Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPCR Structure Therapeutics	$19.61 +1.2%	$19.24	$13.22 ▼ $45.37	$1.13B	-1.89	922,813 shs	544,304 shs
RCUS Arcus Biosciences	$10.51 +0.3%	$9.25	$6.50 ▼ $18.98	$1.12B	0.89	809,959 shs	726,948 shs
VERV Verve Therapeutics	$11.13	$11.03	$2.86 ▼ $11.40	$992.13M	2.23	3.94 million shs	N/A
VOR Vor Biopharma	$2.17	$1.78	$0.13 ▼ $3.29	$274.90M	2.06	7.88 million shs	2.86 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPCR Structure Therapeutics	+1.24%	-2.53%	+7.98%	-20.12%	-50.53%
RCUS Arcus Biosciences	+0.13%	+1.15%	+7.84%	+16.19%	-40.49%
VERV Verve Therapeutics	0.00%	0.00%	+0.27%	+155.28%	+117.38%
VOR Vor Biopharma	0.00%	+1.40%	+3.83%	+1,128.77%	+117.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GPCR Structure Therapeutics	2.6298 of 5 stars	3.5	3.0	1.9	1.7	0.6
RCUS Arcus Biosciences	2.3996 of 5 stars	3.4	3.0	2.8	1.7	0.0
VERV Verve Therapeutics	2.9778 of 5 stars	4.2	4.0	0.6	2.5	0.0
VOR Vor Biopharma	1.9474 of 5 stars	3.3	0.0	1.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GPCR Structure Therapeutics	3.00	Buy	$75.71	286.10% Upside
RCUS Arcus Biosciences	2.75	Moderate Buy	$21.14	101.19% Upside
VERV Verve Therapeutics	2.33	Hold	$14.57	30.92% Upside
VOR Vor Biopharma	2.56	Moderate Buy	$6.07	179.57% Upside

Current Analyst Ratings Breakdown

Latest VOR, GPCR, VERV, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
8/7/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $60.00
8/7/2025	GPCR Structure Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$92.00 ➝ $90.00
8/7/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$89.00 ➝ $87.00
8/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$26.00 ➝ $25.00
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/27/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$20.00 ➝ $13.50
6/26/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$13.40 per share	N/A
RCUS Arcus Biosciences	$258M	4.34	N/A	N/A	$5.16 per share	2.04
VERV Verve Therapeutics	$32.33M	30.69	N/A	N/A	$5.83 per share	1.91
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GPCR Structure Therapeutics	-$122.53M	-$1.05	N/A	N/A	N/A	N/A	-21.31%	-20.34%	N/A
RCUS Arcus Biosciences	-$283M	-$3.17	N/A	N/A	N/A	-109.56%	-55.96%	-25.73%	11/5/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	N/A
VOR Vor Biopharma	N/A	-$13.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest VOR, GPCR, VERV, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	-$0.36	-$0.08	-$0.36	N/A	N/A
8/6/2025	Q2 2025	RCUS Arcus Biosciences	-$1.14	-$1.1053	+$0.0347	N/A	$32.86 million	$160.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GPCR Structure Therapeutics	N/A	20.48	20.48
RCUS Arcus Biosciences	0.18	4.50	4.50
VERV Verve Therapeutics	N/A	9.84	9.84
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GPCR Structure Therapeutics	91.78%
RCUS Arcus Biosciences	92.89%
VERV Verve Therapeutics	97.11%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
GPCR Structure Therapeutics	5.60%
RCUS Arcus Biosciences	9.60%
VERV Verve Therapeutics	19.30%
VOR Vor Biopharma	0.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GPCR Structure Therapeutics	136	57.60 million	54.37 million	Optionable
RCUS Arcus Biosciences	500	106.43 million	96.21 million	Optionable
VERV Verve Therapeutics	110	89.14 million	71.94 million	Optionable
VOR Vor Biopharma	140	126.68 million	65.45 million	Not Optionable

VOR, GPCR, VERV, and RCUS Headlines

Recent News About These Companies

Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 19, 2025 | finanznachrichten.de

Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright

August 19, 2025 | marketbeat.com

Vor Biopharma Q3 EPS Forecast Decreased by HC Wainwright

August 19, 2025 | americanbankingnews.com

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2025 | globenewswire.com

Analysts Set Expectations for Vor Biopharma FY2028 Earnings

August 17, 2025 | marketbeat.com

Wedbush Brokers Boost Earnings Estimates for Vor Biopharma

August 17, 2025 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Vor Biopharma

August 17, 2025 | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Given "Buy" Rating at HC Wainwright

August 17, 2025 | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Receives "Buy" Rating from HC Wainwright

August 16, 2025 | marketbeat.com

Wedbush Comments on Vor Biopharma's Q3 Earnings (NYSE:VOR)

August 16, 2025 | americanbankingnews.com

Vor Biopharma Shares Soar on Positive Results for Autoimmune-Disorder Treatment

August 13, 2025 | marketwatch.com

Vor says drug licensed from RemeGen succeeded in Sjögren’s study

August 13, 2025 | finance.yahoo.com

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

August 13, 2025 | benzinga.com

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

August 13, 2025 | globenewswire.com

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

August 4, 2025 | globenewswire.com

Vor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?

July 30, 2025 | marketbeat.com

Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 30, 2025 | marketbeat.com

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

July 29, 2025 | insidermonkey.com

Vor Biopharma Announces Key Leadership Changes

July 25, 2025 | theglobeandmail.com

Vor Biopharma Inc.'s (NASDAQ:VOR) top holders are insiders and they are likely disappointed by the recent 14% drop

July 23, 2025 | finance.yahoo.com

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

July 21, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VOR, GPCR, VERV, and RCUS Company Descriptions

Structure Therapeutics NASDAQ:GPCR

$19.61 +0.24 (+1.24%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$19.92 +0.32 (+1.61%)

As of 08/22/2025 05:12 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Arcus Biosciences NYSE:RCUS

$10.51 +0.03 (+0.28%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$10.60 +0.09 (+0.87%)

As of 08/22/2025 04:10 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Verve Therapeutics NASDAQ:VERV

$11.13 0.00 (0.00%)

As of 07/25/2025

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma NYSE:VOR

$2.17 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.19 +0.02 (+1.15%)

As of 08/22/2025 07:53 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time